Clinical Trials
12
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma
- Conditions
- Advanced Solid TumorsRelapsed Or Refractory Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
- Target Recruit Count
- 38
- Registration Number
- NCT05564806
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma
- Conditions
- Mucosal Melanoma
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT05420324
- Locations
- 🇨🇳
Cancer Hospital of Fujian, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Cancer Hospital of Zhenzhou, Zhengzhou, Henan, China
A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
- Registration Number
- NCT05212922
- Locations
- 🇦🇲
Gabrail Cancer Center Research, Canton, Ohio, Armenia
🇦🇺University of New South Wales (UNSW) - Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺Andrew Love Cancer Centre, Geelong, Victoria, Australia
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
- Target Recruit Count
- 5
- Registration Number
- NCT05176509
- Locations
- 🇦🇺
Blacktown Cancer and Haematology Centre, Clinical Trials, Block C, Level 3, 18 Blacktown Road, Blacktown, New South Wales, Australia
🇦🇺"Oncology Clinical Trial Unit St George Private Hospital 1 South Street", Kogarah, New South Wales, Australia
🇦🇺55 Commercial Rd, Level 2 WBRC, Melbourne, Victoria, Australia
A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: YH002+YH001
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT05169697
- Locations
- 🇦🇺
Orange Health Services, Orange, New South Wales, Australia
🇦🇺Macquarie University Hospital, Sydney, New South Wales, Australia
🇦🇺Peninsula and South Eastern Haematology & Oncology Group, Frankston, Victoria, Australia
- Prev
- 1
- 2
- 3
- Next